Literature DB >> 24676844

Biochemical markers of bone turnover in diabetes patients--a meta-analysis, and a methodological study on the effects of glucose on bone markers.

J Starup-Linde1, S A Eriksen, S Lykkeboe, A Handberg, P Vestergaard.   

Abstract

UNLABELLED: This study examined whether markers of bone turnover differ between individuals with and without diabetes. Bone markers showed heterogeneity between studies and were discrepant for markers of bone creation and markers of bone degradation. Bone markers may be of lesser value in diabetes due to heterogeneity.
INTRODUCTION: The aim of this meta-analysis was to compare existing literature regarding changes in bone markers among diabetics compared to healthy controls. To exclude that blood glucose levels among diabetes patients could influence the assays used for determining bone turnover markers, a methodological study was performed.
METHODS: Medline at Pubmed Embase, Cinahl, Svemed+, Cochrane library, and Bibliotek.dk was searched in August 2012. The studies should examine biochemical bone turnover among diabetes patients in comparison to controls in an observational design. In the methodological study, fasting blood samples were drawn from two individuals. Glucose was added to the blood samples in different concentrations and OC, CTX, and procollagen type 1 amino terminal propeptide were measured after 0, 1, 2, and 3 h.
RESULTS: Twenty-two papers fulfilled the criteria for the meta-analysis. From the pooled data in the meta-analysis, the bone markers osteocalcin (OC) (-1.15 ng/ml [-1.78,-0.52]) and C-terminal cross-linked telopeptide (CTX) (-0.14 ng/ml [-0.22, -0.05]) were significantly lower among diabetes patients than non-diabetes patients, however other markers did not differ. All markers displayed very high heterogeneity by I2 statistics. In the methodological study, the addition of glucose did not significantly change the bone markers neither by level of glucose nor with increasing incubation time.
CONCLUSION: The dissociative pattern of biochemical bone markers of bone formation and bone resorption present in diabetes patients is thus not caused by glucose per se but may be modulated by unknown factors associated with diabetes mellitus.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24676844     DOI: 10.1007/s00198-014-2676-7

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  46 in total

Review 1.  The amino- and carboxyterminal cross-linked telopeptides of collagen type I, NTX-I and CTX-I: a comparative review.

Authors:  Markus Herrmann; Markus J Seibel; Markus Seibel
Journal:  Clin Chim Acta       Date:  2008-03-27       Impact factor: 3.786

2.  Sex- and age-related changes in bone and serum osteocalcin.

Authors:  D Vanderschueren; G Gevers; G Raymaekers; P Devos; J Dequeker
Journal:  Calcif Tissue Int       Date:  1990-03       Impact factor: 4.333

3.  Parathormone--25(OH)-vitamin D axis and bone status in children and adolescents with type 1 diabetes mellitus.

Authors:  Enas A Hamed; Nagla H Abu Faddan; Hebh A Adb Elhafeez; Douaa Sayed
Journal:  Pediatr Diabetes       Date:  2011-03-22       Impact factor: 4.866

4.  Bone structure and turnover in type 2 diabetes mellitus.

Authors:  A Shu; M T Yin; E Stein; S Cremers; E Dworakowski; R Ives; M R Rubin
Journal:  Osteoporos Int       Date:  2011-03-19       Impact factor: 4.507

5.  Bone density, body composition, and markers of bone remodeling in type 1 diabetic patients.

Authors:  Soha M Abd El Dayem; Amal M El-Shehaby; Asmat Abd El Gafar; Ashraf Fawzy; Hassan Salama
Journal:  Scand J Clin Lab Invest       Date:  2011-04-08       Impact factor: 1.713

6.  Serum osteocalcin (BGP) levels in normal men: a longitudinal evaluation reveals an age-associated increase.

Authors:  E S Orwoll; L J Deftos
Journal:  J Bone Miner Res       Date:  1990-03       Impact factor: 6.741

Review 7.  Gone with the Wnts: beta-catenin, T-cell factor, forkhead box O, and oxidative stress in age-dependent diseases of bone, lipid, and glucose metabolism.

Authors:  Stavros C Manolagas; Maria Almeida
Journal:  Mol Endocrinol       Date:  2007-07-10

8.  Significant inverse relationship between serum undercarboxylated osteocalcin and glycemic control in maintenance hemodialysis patients.

Authors:  S Okuno; E Ishimura; N Tsuboniwa; K Norimine; K Yamakawa; T Yamakawa; S Shoji; K Mori; Y Nishizawa; M Inaba
Journal:  Osteoporos Int       Date:  2012-05-12       Impact factor: 4.507

9.  International Osteoporosis Foundation and International Federation of Clinical Chemistry and Laboratory Medicine position on bone marker standards in osteoporosis.

Authors:  Samuel Vasikaran; Cyrus Cooper; Richard Eastell; Andrea Griesmacher; Howard A Morris; Tommaso Trenti; John A Kanis
Journal:  Clin Chem Lab Med       Date:  2011-05-24       Impact factor: 3.694

10.  Young women with type 1 diabetes have lower bone mineral density that persists over time.

Authors:  Lucy D Mastrandrea; Jean Wactawski-Wende; Richard P Donahue; Kathleen M Hovey; Angela Clark; Teresa Quattrin
Journal:  Diabetes Care       Date:  2008-06-30       Impact factor: 19.112

View more
  59 in total

Review 1.  Epidemiology of Skeletal Health in Type 1 Diabetes.

Authors:  David R Weber; George Schwartz
Journal:  Curr Osteoporos Rep       Date:  2016-12       Impact factor: 5.096

2.  Age- and sex-specific association of circulating osteocalcin with dynamic measures of glucose homeostasis.

Authors:  K Y Jung; K M Kim; E J Ku; Y J Kim; D-H Lee; S H Choi; H C Jang; C S Shin; K S Park; S Lim
Journal:  Osteoporos Int       Date:  2015-09-15       Impact factor: 4.507

Review 3.  Assessment of bone quality in patients with diabetes mellitus.

Authors:  N Jiang; W Xia
Journal:  Osteoporos Int       Date:  2018-05-07       Impact factor: 4.507

4.  Hypogonadal men with type 2 diabetes mellitus have smaller bone size and lower bone turnover.

Authors:  Georgia Colleluori; Lina Aguirre; Richard Dorin; David Robbins; Dean Blevins; Yoann Barnouin; Rui Chen; Clifford Qualls; Dennis T Villareal; Reina Armamento-Villareal
Journal:  Bone       Date:  2017-03-16       Impact factor: 4.398

5.  Risk of low-energy fracture in type 2 diabetes patients: a meta-analysis of observational studies.

Authors:  P Jia; L Bao; H Chen; J Yuan; W Liu; F Feng; J Li; H Tang
Journal:  Osteoporos Int       Date:  2017-08-09       Impact factor: 4.507

6.  Diabetes and Abdominal Aortic Calcification-a Systematic Review.

Authors:  Emilie Frey Bendix; Eskild Johansen; Thomas Ringgaard; Martin Wolder; Jakob Starup-Linde
Journal:  Curr Osteoporos Rep       Date:  2018-02       Impact factor: 5.096

7.  Advanced Glycation Endproducts and Bone Material Strength in Type 2 Diabetes.

Authors:  Jessica R Furst; Leonardo C Bandeira; Wen-Wei Fan; Sanchita Agarwal; Kyle K Nishiyama; Donald J McMahon; Elzbieta Dworakowski; Hongfeng Jiang; Shonni J Silverberg; Mishaela R Rubin
Journal:  J Clin Endocrinol Metab       Date:  2016-04-26       Impact factor: 5.958

Review 8.  Efficacy of anti-osteoporotic medications in patients with type 1 and 2 diabetes mellitus: a systematic review.

Authors:  Panagiotis Anagnostis; Stavroula A Paschou; Nifon N Gkekas; Aikaterini-Maria Artzouchaltzi; Konstantinos Christou; Dimitrios Stogiannou; Andromachi Vryonidou; Michael Potoupnis; Dimitrios G Goulis
Journal:  Endocrine       Date:  2018-02-06       Impact factor: 3.633

9.  Sclerostin Regulation, Microarchitecture, and Advanced Glycation End-Products in the Bone of Elderly Women With Type 2 Diabetes.

Authors:  Alessandra Piccoli; Francesca Cannata; Rocky Strollo; Claudio Pedone; Giulia Leanza; Fabrizio Russo; Valentina Greto; Camilla Isgrò; Carlo Cosimo Quattrocchi; Carlo Massaroni; Sergio Silvestri; Gianluca Vadalà; Tiziana Bisogno; Vincenzo Denaro; Paolo Pozzilli; Simon Y Tang; Matt J Silva; Caterina Conte; Rocco Papalia; Mauro Maccarrone; Nicola Napoli
Journal:  J Bone Miner Res       Date:  2020-10-02       Impact factor: 6.741

Review 10.  Impact of Type 2 Diabetes Mellitus and Antidiabetic Medications on Bone Metabolism.

Authors:  Hae Sang Lee; Jin Soon Hwang
Journal:  Curr Diab Rep       Date:  2020-11-27       Impact factor: 4.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.